Xenon Pharmaceuticals Inc. $XENE is Braidwell LP’s 10th Largest Position

Braidwell LP trimmed its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 15.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,131,452 shares of the biopharmaceutical company’s stock after selling 207,000 shares during the quarter. Xenon Pharmaceuticals comprises approximately 2.5% of Braidwell LP’s portfolio, making the stock its 10th biggest position. Braidwell LP owned approximately 1.17% of Xenon Pharmaceuticals worth $68,294,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Danske Bank A S acquired a new position in shares of Xenon Pharmaceuticals in the 3rd quarter valued at $32,000. Kestra Advisory Services LLC acquired a new position in Xenon Pharmaceuticals in the fourth quarter valued at $33,000. Osaic Holdings Inc. boosted its stake in Xenon Pharmaceuticals by 541.4% in the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 1,034 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Xenon Pharmaceuticals during the fourth quarter worth about $43,000. Finally, Rockefeller Capital Management L.P. increased its position in shares of Xenon Pharmaceuticals by 450.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,100 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 900 shares in the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Trading Up 0.3%

XENE stock opened at $60.16 on Thursday. The firm has a 50 day moving average of $63.49 and a 200-day moving average of $56.86. Xenon Pharmaceuticals Inc. has a 12-month low of $35.60 and a 12-month high of $72.66. The company has a market cap of $5.82 billion, a price-to-earnings ratio of -12.69 and a beta of 0.61.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.05. During the same period in the previous year, the business posted ($1.07) EPS. Sell-side analysts forecast that Xenon Pharmaceuticals Inc. will post -4.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on XENE. Royal Bank Of Canada lowered their target price on shares of Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating on the stock in a research report on Friday, August 7th. Wall Street Zen upgraded Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. JPMorgan Chase & Co. boosted their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a report on Wednesday, May 27th. Wells Fargo & Company reiterated an “overweight” rating and set a $69.00 price target on shares of Xenon Pharmaceuticals in a research note on Sunday, May 10th. Finally, Needham & Company LLC cut their price target on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a report on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $77.13.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Gillian Cannon sold 1,190 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $63,236.60. Following the sale, the director owned 1,455 shares of the company’s stock, valued at $77,318.70. This represents a 44.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Christopher John Kenney sold 7,068 shares of the stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $60.25, for a total transaction of $425,847.00. Following the completion of the sale, the insider owned 2 shares in the company, valued at $120.50. This represents a 99.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 19,580 shares of company stock valued at $1,199,935. Insiders own 2.91% of the company’s stock.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical?stage biopharmaceutical company dedicated to discovering and developing novel, small?molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion?channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion?channel biology and structure?based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.